atp5f1b-protein
<div class="infobox infobox-protein">
<table style="width:100%; background:transparent;">
<tr><th colspan="2" style="background:#e8f4f8;">ATP5F1B Protein</th></tr>
<tr><td><b>Gene</b></td><td>ATP5F1B (ATP Synthase Subunit Beta)</td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/P06576">P06576</a></td></tr>
<tr><td><b>Alternative Names</b></td><td>ATP synthase subunit beta, ATPB, ATPMB</td></tr>
<tr><td><b>PDB Structures</b></td><td>1BM1, 2CW4, 5ARA</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~56 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Mitochondrial inner membrane</td></tr>
<tr><td><b>Protein Family</b></td><td>F-type ATP synthase, H+-transporting ATPase complex</td></tr>
</table>
</div>
Overview
ATP5F1B (ATP Synthase Subunit Beta, encoded by the ATP5F1B gene) is the catalytic beta subunit of the mitochondrial F1 sector of ATP synthase (Complex V), the terminal enzyme of the oxidative phosphorylation (OXPHOS) chain. This protein catalyzes the conversion of ADP and inorganic phosphate (Pi) to ATP using the proton gradient generated by the electron transport chain. In the nervous system, ATP5F1B is essential for maintaining neuronal energy homeostasis, and its dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders [@lin2005].
Structure
ATP5F1B is the catalytic core of the F1-ATPase complex. The protein contains several structurally and functionally distinct domains:
Catalytic Domains
...
atp5f1b-protein
<div class="infobox infobox-protein">
<table style="width:100%; background:transparent;">
<tr><th colspan="2" style="background:#e8f4f8;">ATP5F1B Protein</th></tr>
<tr><td><b>Gene</b></td><td>ATP5F1B (ATP Synthase Subunit Beta)</td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/P06576">P06576</a></td></tr>
<tr><td><b>Alternative Names</b></td><td>ATP synthase subunit beta, ATPB, ATPMB</td></tr>
<tr><td><b>PDB Structures</b></td><td>1BM1, 2CW4, 5ARA</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~56 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Mitochondrial inner membrane</td></tr>
<tr><td><b>Protein Family</b></td><td>F-type ATP synthase, H+-transporting ATPase complex</td></tr>
</table>
</div>
Overview
ATP5F1B (ATP Synthase Subunit Beta, encoded by the ATP5F1B gene) is the catalytic beta subunit of the mitochondrial F1 sector of ATP synthase (Complex V), the terminal enzyme of the oxidative phosphorylation (OXPHOS) chain. This protein catalyzes the conversion of ADP and inorganic phosphate (Pi) to ATP using the proton gradient generated by the electron transport chain. In the nervous system, ATP5F1B is essential for maintaining neuronal energy homeostasis, and its dysfunction is implicated in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders [@lin2005].
Structure
ATP5F1B is the catalytic core of the F1-ATPase complex. The protein contains several structurally and functionally distinct domains:
Catalytic Domains
The beta subunit contains the catalytic machinery for ATP synthesis:
- Nucleotide binding domain: Binds ADP and ATP at three catalytic sites
- Rotation transmission domain: Couples rotation to proton translocation
- Central stalk interface: Interfaces with the gamma subunit to transmit rotation
- Oligomycin sensitivity conferral site: Region conferring oligomycin sensitivity to the complex
Structural Features
Crystal structures reveal a hexameric arrangement of alternating alpha and beta subunits:
- Alpha-beta hexamer: Six subunits (3 alpha, 3 beta) forming a ring
- Rotational catalysis: Beta subunit undergoes conformational changes during rotation
- Central stalk: Gamma subunit rotates within the alpha/beta hexamer
Comparison with Other Species
ATP5F1B is highly conserved across eukaryotes, reflecting its essential role in energy metabolism.
Normal Function
ATP5F1B is central to mitochondrial oxidative phosphorylation, the primary mechanism for ATP production in aerobic cells:
ATP Synthesis Mechanism
The beta subunit catalyzes the final step in oxidative phosphorylation:
Proton gradient: Electron transport chain pumps protons across the inner membrane
F0 channel: Protons flow back through the F0 sector
Rotational coupling: Proton flow drives rotation of the gamma subunit
Conformational change: Beta subunit transitions through three states
ATP release: Conformational change releases newly synthesized ATPEnergy Production
Each glucose molecule yields approximately 30-32 ATP through oxidative phosphorylation:
- Glycolysis: 2 ATP
- Krebs cycle: 2 ATP
- Oxidative phosphorylation: ~28 ATP
Regulation of ATP5F1B
The beta subunit is regulated at multiple levels:
- Transcriptional control: Nuclear、呼吸链and mitochondria-encoded subunits coordinated
- Post-translational modification: Phosphorylation affects activity
- Product inhibition: ATP:ADP ratio feedback inhibits activity
- Calcium regulation: Ca2+ influences mitochondrial ATP production
Role in the Electron Transport Chain
ATP5F1B works in concert with other Complex V subunits:
- F0 sector: Proton channel (subunits a, A6L, b, c-ring)
- F1 sector: Catalytic core (alpha3beta3, gamma, delta, epsilon)
- Peripheral stalk: Stabilizes the complex
- OSCP: Oligomycin sensitivity conferral protein
Role in the Nervous System
In neurons, ATP5F1B is critical for maintaining energy homeostasis in highly energy-demanding cells:
Neuronal Energy Requirements
Neurons have exceptionally high energy demands:
- Resting potential: Maintaining ion gradients requires constant ATP
- Action potentials: Regeneration requires ATP-dependent pumps
- Synaptic transmission: Neurotransmitter release is ATP-intensive
- Axonal transport: ATP powers molecular motors
- Protein synthesis: Local translation at synapses
Brain-Specific Expression
ATP5F1B is highly expressed in:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (CA1 pyramidal neurons)
- Cerebellum (Purkinje cells)
- Substantia nigra (dopaminergic neurons)
- Spinal cord (motor neurons)
Synaptic Function
ATP5F1B supports specialized neuronal functions:
- Synaptic vesicle cycling: ATP for vesicle release/recycling
- Dendritic spines: High energy demand for plasticity
- Axonal mitochondria: Energy for transport
- Presynaptic terminals: Dense mitochondrial networks
Role in Neurodegeneration
Alzheimer's Disease (AD)
Mitochondrial dysfunction is a hallmark of AD, with ATP5F1B playing a central role [@ryan2012]:
Reduced Complex V activity: ATP synthase activity decreases in AD brain
Amyloid-beta interaction: Aβlocalizes to mitochondria and impairs function
Tau pathology: Affects mitochondrial transport and distribution
Bioenergetic deficits: Reduced ATP production in neurons
Calcium dysregulation: Impaired mitochondrial Ca2+ handlingParkinson's Disease (PD)
ATP5F1B is particularly relevant to PD pathogenesis [@perier2012]:
Dopaminergic neuron vulnerability: High energy demand makes these neurons susceptible
Mitochondrial Complex I deficiency: Often accompanied by Complex V defects
LRRK2 mutations: Affect mitochondrial dynamics and function
PINK1/Parkin pathway: Links mitophagy to bioenergetic defects
Alpha-synuclein: May impair mitochondrial function directlyAmyotrophic Lateral Sclerosis (ALS)
ATP5F1B contributes to motor neuron degeneration [@bhattacharya2014]:
Energy deficit: Reduced ATP production in motor neurons
Mitochondrial dysfunction: Common feature in ALS models
Axonal transport defects: Impaired organelle trafficking
C9orf72 repeat toxicity: Affects mitochondrial function
TDP-43 pathology: Disrupts mitochondrial protein homeostasisHuntington's Disease
- Mutant huntingtin disrupts mitochondrial function
- ATP5F1B expression altered in HD models
- Bioenergetic deficits contribute to neuronal dysfunction
Other Neurodegenerative Conditions
- Friedreich's ataxia: Frataxin deficiency affects Complex V
- Leigh syndrome: Mitochondrial ATP production defective
- MELAS: Mitochondrial encephalomyopathy with lactic acidosis
Molecular Mechanisms
Oxidative Phosphorylation Defects
Multiple mechanisms link ATP5F1B to neurodegeneration:
Direct dysfunction: Mutations or post-translational modifications
Indirect impairment: Downstream effects of other defects
Transport defects: Reduced mitochondrial distribution
Quality control: Impaired mitochondrial biogenesisCalcium Dysregulation
ATP5F1B dysfunction affects calcium handling:
- Reduced Ca2+ uptake: ATP-dependent transporters affected
- Excitotoxicity: Impaired buffer capacity
- Synaptic dysfunction: Calcium-dependent plasticity impaired
Reactive Oxygen Species
Mitochondrial dysfunction increases oxidative stress:
- Electron leak: Increased ROS from ETC
- Direct ROS damage: To proteins, lipids, DNA
- Peroxynitrite formation: Nitrosative stress
Therapeutic Implications
Energy-Targeting Approaches
- Mitochondrial CoQ10: Supports electron transport
- L-carnitine: Enhances fatty acid oxidation
- Alpha-lipoic acid: Antioxidant and metabolic support
Small Molecule Interventions
- mTOR inhibitors: May improve mitochondrial function [@johnson2010]
- AMPK activators: Promote mitochondrial biogenesis
- NAD+ precursors: Support sirtuin activity
Gene Therapy Approaches
- ATP5F1B overexpression: Enhance ATP production
- Mitochondrial targeting: Improve distribution
- CRISPR activation: Upregulate functional expression
Drug Development Targets
ATP synthase activators: Enhance catalytic function
Mitochondrial protectants: Reduce oxidative damage
Biogenesis promoters: Increase mitochondrial mass
Metabolic modulators: Optimize substrate utilizationMermaid Diagram: ATP5F1B in Neuronal Energy and Neurodegeneration
Mermaid diagram (expand to render)
Cross-links
- [ATP5F1B Gene](/content/genes)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Mitochondria](/mechanisms/mitochondria)
External Links
- [UniProt: ATP5F1B](https://www.uniprot.org/uniprot/P06576)
- [NCBI Gene: ATP5F1B](https://www.ncbi.nlm.nih.gov/gene/547)
- [PDB: ATP Synthase Structures](https://www.rcsb.org/)
- [KEGG: Oxidative Phosphorylation](https://www.genome.jp/kegg/pathway.html)
- [PubMed: ATP5F1B Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ATP5F1B+neurodegeneration)
See Also
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
- [Complex V](/mechanisms/complex-v)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
References
[Hatefi Y, The mitochondrial electron transport chain and ATP synthase (1985)](https://doi.org/10.1146/annurev.bi.54.070185.002045)
[Capaldi RA, et al., Molecular basis of vertebrate mitochondrial metabolism (1988)](https://pubmed.ncbi.nlm.nih.gov/3041254/)
[Wallace DC, Mitochondrial genetics: a paradigm for aging and degenerative diseases (1992)](https://pubmed.ncbi.nlm.nih.gov/1560860/)
[Bossy-Wetzel E, et al., Mitochondria in neurodegeneration (1998)](https://pubmed.ncbi.nlm.nih.gov/9818333/)
[Mattson MP, et al., Mitochondria in neuronal survival and death (1999)](https://pubmed.ncbi.nlm.nih.gov/10648849/)
[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)](https://pubmed.ncbi.nlm.nih.gov/17051217/)
[Sayre LM, et al., Iron and aluminum in neurodegenerative diseases (2000)](https://pubmed.ncbi.nlm.nih.gov/10739480/)
[Perier C, et al., Mitochondrial bioenergetics in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22825450/)
[Ryan T, et al., Mitochondria and Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22569937/)
[Bhattacharya K, et al., Mitochondrial dysfunction in ALS (2014)](https://pubmed.ncbi.nlm.nih.gov/24809813/)
[Van Leene J, et al., The Arabidopsis mitochondrial proteome (2011)](https://pubmed.ncbi.nlm.nih.gov/21849420/)
[Johnson SC, et al., mTOR inhibition induces oxidative stress and improves brain function (2010)](https://pubmed.ncbi.nlm.nih.gov/20023430/)
[Manji H, et al., Mitochondrial dysfunction in mood disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22781201/)
[Schon EA, Przyborski SA, Mitochondria and neurodegeneration: the plot thickens (2012)](https://pubmed.ncbi.nlm.nih.gov/22542842/)
[Devin A, et al., Bioenergetic analysis of mitochondrial function (2010)](https://pubmed.ncbi.nlm.nih.gov/20497822/)
[Taylor RC, et al., Quality control in mitochondrial protein synthesis (2013)](https://pubmed.ncbi.nlm.nih.gov/23502475/)
[Zhang X, et al., Mitochondrial ATP synthase in aging and longevity (2015)](https://pubmed.ncbi.nlm.nih.gov/25692645/)
[Vafai SB, et al., Mitochondrial disorders and the nervous system (2016)](https://pubmed.ncbi.nlm.nih.gov/27094180/)
[Strobelt S, et al., Mitochondrial ATP synthase in synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32868123/)
[Moreno JA, et al., Targeting mitochondrial ATP synthase in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)